NYSEAMERICAN:MTNB Matinas Biopharma (MTNB) Stock Price, News & Analysis $0.16 0.00 (-1.60%) As of 09/18/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Matinas Biopharma Stock (NYSEAMERICAN:MTNB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Matinas Biopharma alerts:Sign Up Key Stats Today's Range$0.16▼$0.1750-Day Range$0.16▼$0.4852-Week Range$0.15▼$2.14Volume425,929 shsAverage Volume817,764 shsMarket Capitalization$2.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract. Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections. The company has evaluated MAT2203 in clinical studies for conditions including cryptococcal meningitis and other invasive fungal infections. The product remains investigational and is not approved for commercial use. The company has also developed additional LNC-based programs, including MAT2501, an investigational oral formulation of amikacin intended for potential use in treating certain difficult-to-manage bacterial infections. Matinas BioPharma is headquartered in the United States and has focused its activities on research, clinical development and potential partnerships for its drug-delivery platform and product candidates.AI Generated. May Contain Errors. Read More Matinas Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreMTNB MarketRank™: Matinas Biopharma scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Matinas Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas Biopharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas Biopharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas Biopharma has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.22% of the float of Matinas Biopharma has been sold short.Short Interest Ratio / Days to CoverMatinas Biopharma has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas Biopharma has recently increased by 39.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMatinas Biopharma does not currently pay a dividend.Dividend GrowthMatinas Biopharma does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.44 News SentimentMatinas Biopharma has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Matinas Biopharma this week, compared to 0 articles on an average week.Search Interest1 people have searched for MTNB on MarketBeat in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Matinas Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.60% of the stock of Matinas Biopharma is held by insiders.Percentage Held by Institutions11.77% of the stock of Matinas Biopharma is held by institutions.Read more about Matinas Biopharma's insider trading history. Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTNB Stock News HeadlinesMatinas Biopharma (NYSEAMERICAN:MTNB) Shares Set to Reverse Split on Monday, September 28thSeptember 20 at 1:20 AM | americanbankingnews.comGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputSeptember 14, 2026 | globenewswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.September 20 at 1:00 AM | Porter & Company (Ad)Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsSeptember 4, 2026 | globenewswire.comGH Power, Matinas BioPharma join forces to create NYSE-listed clean energy companyJuly 13, 2026 | msn.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...July 13, 2026 | markets.businessinsider.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsJuly 13, 2026 | globenewswire.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceJune 26, 2026 | globenewswire.comSee More Headlines MTNB Stock Analysis - Frequently Asked Questions How have MTNB shares performed this year? Matinas Biopharma's stock was trading at $0.5860 at the start of the year. Since then, MTNB stock has decreased by 72.6% and is now trading at $0.1604. How were Matinas Biopharma's earnings last quarter? Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter. When did Matinas Biopharma's stock split? Shares of Matinas Biopharma reverse split on Monday, September 28th 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Matinas Biopharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Matinas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include SCYNEXIS (SCYX), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). Company Calendar Last Earnings8/13/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MTNB's financial health is in the Red zone, according to TradeSmith. MTNB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:MTNB Previous SymbolNYSE:MTNB CIK1582554 Webmatinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($3.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.11% Return on Assets-102.20% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$1.10 million Price / Sales2.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book0.21Miscellaneous Outstanding Shares14,690,000Free Float14,017,000Market Cap$2.36 million OptionableN/A Beta1.70 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSEAMERICAN:MTNB) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
